Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant

Next Previous
Trial Profile

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QEL-001 (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions; First in man
  • Acronyms LIBERATE
  • Sponsors Quell Therapeutics

Most Recent Events

  • 03 Mar 2026 According to a Quell Therapeutics media release, the company plans to provide further clinical and translational data from the LIBERATE study at key international medical congresses in 2026 and via peer-reviewed publication.
  • 03 Mar 2026 Results presented in a Quell Therapeutics Media Release.
  • 24 Feb 2026 Planned End Date changed from 1 Mar 2040 to 1 Sep 2040.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top